Roundtable Discussion: McKay Covers First-Line Decision-Making for Metastatic RCC
December 20th 2022During a Targeted Oncology case-based roundtable event, Rana McKay, MD, and participants discussed the case of a patient with previously untreated advanced renal cell carcinoma with favorable risk status.
Matasar Looks at Various Treatment Options in the DLBCL Setting for Transplant-Ineligble Patients
December 19th 2022During a Targeted Oncology case-based roundtable event, Matthew Matasar, MD, MS, discussed the case of a patient with diffuse large B-cell lymphoma who relapsed 18 months following frontline combination therapy.
Roundtable Discussion: Forde Reviews Chemoimmunotherapy as Treatment for Squamous NSCLC
December 19th 2022During a Targeted Oncology case-based roundtable event, Patrick Forde, MBBCh, discussed the use of the regimen consisting of nivolumab, ipilimumab, and 2 cycles of chemotherapy for non–small cell lung cancer.
Considerations on Tolerability of Cabazitaxel in mCRPC
December 16th 2022During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants their experiences with using cabazitaxel in patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.
Patient Selection Considerations for CheckMate 9LA Regimen in NSCLC
December 14th 2022During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed with participants which patients are candidates for chemoimmunotherapy for advanced non–small cell lung cancer. This is the second of 2 articles based on this event.
Phillips Evaluates Second-Line Therapy Options for R/R DLBCL
December 14th 2022During a Targeted Oncology case-based roundtable event, Tycel Phillips, MD, discussed available therapies for a patient with relapsed/refractory diffuse large B-cell lymphoma including CAR T-cell therapy and combination systemic therapies.
PD-L1 CPS Plays Role in Selecting Treatment for Gastric Cancer
December 9th 2022During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed the addition of nivolumab to chemotherapy for patients with gastric/gastroesophageal junction cancer based on PD-L1 status. This is the second of 2 articles based on this event.
Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC
December 5th 2022During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.
Lancet Reviews the Key Treatment Options for BPDCN
December 2nd 2022During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the data behind tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.
Discussing the Role of Cabazitaxel Post–Hormone Therapy for mCRPC
November 30th 2022During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.
Clinical Commentary: Dose Reduction of Selinexor in Relapsed Patients With Multiple Myeloma
November 29th 2022At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.
Roundtable Discussion: Looking at the Role of Avelumab Maintenance in Metastatic Bladder Cancer
November 29th 2022During a Targeted Oncology case-based roundtable event, Daniel Petrylak, MD, discussed with participants the case of a patient with bladder cancer who has lung metastases and significant pulmonary comorbidities.
Roundtable Discussion: Savvides Analyzes Role of Hedgehog Inhibitors and Immunotherapy in BCC
November 29th 2022During a Targeted Oncology case-based roundtable event, Panayiotis S. Savvides, MD, PhD, MPH, discussed with participants their experiences using hedgehog pathway inhibitors and immunotherapy for patients with basal cell carcinoma.
Reviewing 3-Year Updated Data From CheckMate 9LA for NSCLC
November 28th 2022During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed 3-year data on overall survival and subgroup analysis for the CheckMate 9LA trial of ipilimumab, nivolumab, and 2 cycles of chemotherapy.